VR ADVISER, LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

9

of those in investment advisory functions:

9

Registration:

SEC, Approved, 4/9/2014

AUM:

2,891,501,332 19.62%

of that, discretionary:

2,891,501,332 19.62%

GAV:

2,891,501,332 19.62%

Avg Account Size:

361,437,667 19.62%

SMA’s:

NO

Private Funds:

8

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
2B 2B 2B 1B 1B 691M 345M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

VR Adviser, LLC Buys Kinnate Biopharma Inc, Aclaris Therapeutics Inc, Pharvaris NV, Sells Keros ...
05/14/2021

Related Stocks: ACRS, VTGN, CLDX, RLMD, KNTE, PHVS, EPIX, ACET, APTO, EYPT,

gurufocus.com

Let’s Jump into the Altimmune, Inc. (NASDAQ:ALT) Stock Forecast
03/29/2021

In the last trading session, 1,232,953 Altimmune, Inc. (NASDAQ:ALT) shares changed hands as the company’s beta touched 1.67. With the company’s per share price at $13.85 changed hands at -$0.27 or -0.

marketingsentinel.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Has Recovered 83.25% So Far, But Another 52.15% Gain Cannot Be Ruled Out
03/25/2021

In last trading session, VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw 1,882,435 shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $2.09 trading at -$0.

marketingsentinel.com

Altimmune, Inc. (NASDAQ:ALT) share price rebounds 79.7% from the lows – but can it keep going?
03/25/2021

In last trading session, Altimmune, Inc. (NASDAQ:ALT) saw 1,075,184 shares changing hands with its beta currently measuring 1.7. Company’s recent per share price level of $13.2 trading at -$1.16 or -8.

marketingsentinel.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $1,526,579,261
Private Equity Fund 7 $1,364,922,071

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
OBERLAND CAPITAL MANAGEMENT LLC 6.0m - 3.1b - - - - 3.1b 3.1b 8
TEKNE CAPITAL MANAGEMENT, LLC 510.0m - 546.3m - - - - 1.1b 1.1b 15
SOFTVEST ADVISORS, LLC 473.6m - 54.7m - - - - 528.3m 544.2m 6
VECTOR CAPITAL MANAGEMENT, L.P. 512.9m - 3.5b - - - - 4.0b 4.1b 8
SUN CAPITAL ADVISORS, L.P. 15.7m - 6.6b - - - - 6.6b 6.6b 15
CORSAIR CAPITAL LLC 1.2b - 5.1b - - - - 6.2b 8.4b 47
RRG CAPITAL MANAGEMENT LLC 296.7m - 1.5b - - - - 1.8b 2.5b 8
SAGEVIEW CAPITAL LP 19.5m - 1.6b - - - - 1.6b 2.1b 7
GRATUS CAPITAL, LLC 19.2m - 141.0m - - - - 160.1m 2.7b 7
BURFORD CAPITAL INVESTMENT MANAGEMENT LLC - - 3.4b - - - - 3.4b 3.4b 12

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
03770N101 APOGEE THERAPEUTICS INC $564,381,180 27.00% 138.00% 0.00%
35104E100 4D MOLECULAR THERAPEUTICS IN $140,184,000 7.00% 102.00% 29.00%
67576A100 OCULAR THERAPEUTIX INC $116,138,404 6.00% 235.00% 64.00%
N69605108 PHARVARIS N V $78,472,455 4.00% -18.00% 0.00%
00773J202 SPYRE THERAPEUTICS INC $82,375,691 4.00% 61.00% -8.00%
483497103 KALVISTA PHARMACEUTICALS INC $74,121,810 4.00% 48.00% 53.00%
N5749R100 MERUS N V $80,613,336 4.00% 36.00% -17.00%
29337E102 ENLIVEN THERAPEUTICS INC $70,823,162 3.00% 73.00% 36.00%
68622P109 ORIC PHARMACEUTICALS INC $60,424,746 3.00% 170.00% 81.00%
252828108 DIANTHUS THERAPEUTICS INC $62,831,190 3.00% 551.00% 126.00%

Brochure Summary

Overview

A. VR Adviser, LLC (“VRA” or the “Registrant”), a Delaware limited liability company, is a registered investment adviser with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the Investment Advisers Act of 1940 (the “Adviser Act”). It was established in 2013 and is located in New York and California. VRA serves as an investment adviser to pooled investment vehicles (each, a “Fund” or a “Client”)1, and an affiliate of VRA serves as the general partner (or similar managing body) of each Fund. VR Management, LLC (“VRM”), a Delaware limited liability company, is the sole owner of VRA. Bong Y. Koh, Brian D. Ascher, and Bryan E. Roberts own VRM. VRM has established a committee to govern the affairs of VRA. That committee is overseen by Dr. Koh, Dr. Roberts, and Nimish P. Shah. Mr. Shah is an employee of VRA and is a Member and Director of the General Partners of the Funds. B. VRA provides discretionary investment advisory services solely to Funds. The Venrock Healthcare Capital Partners line of funds (the “VHCP Funds”) focus on long-term investment opportunities in small capitalization public companies and late-stage private companies across all sectors in the healthcare and life sciences industry, with a current emphasis on biopharmaceuticals. Venrock Opportunities Fund, L.P. (the “Opportunities Fund”) focuses on later-stage follow-on investment opportunities in a subset of the public and private portfolio companies, and former portfolio companies, of other VRA-affiliated or VRM-affiliated investment funds, anticipated to be focused primarily on the healthcare and life sciences sector. The Firm seeks to apply a value-driven approach to identify investment opportunities and to apply a primary-sourced, bottom-up, venture capital-like approach in analyzing company specific opportunities for the
Funds. VRA is affiliated with and serves as manager of entities that serve as the general partners to each of the Funds (each, a “General Partner” and, collectively, the “General Partners”, and together with VRA, the “Firm”), and each of the Funds is controlled by its respective General Partner. The following is a list of each of the General Partners, each of which is an affiliated investment adviser of VRA: General Partners:
• VHCP Management, LLC
• VHCP Management II, LLC
• VHCP Management III, LLC
• VHCP Management EG, LLC
• Venrock Opportunities Management, LLC C. The investment focus and risks of the Funds are more particularly described in each Fund’s offering and governing documents. The governing documents of the applicable Fund and its offering 1 “Fund” or “Client” means a private investment fund to which VRA provides investment advice and/or invests on a discretionary or nondiscretionary basis. The individuals and other persons that invest in the VRA private investment funds are generally referred to herein as “investors.” Unless otherwise expressly stated herein, the terms “Fund” and “Client” do not include “investors.” documents set forth the Fund’s specific guidelines. These guidelines may provide for limits on the size, concentration, geography, type of security and/or terms of the Fund’s investments. The Firm does not tailor its advisory services to individual investors in its Funds. D. The Registrant does not participate in wrap fee programs. E. As of December 31, 2022, the Registrant (together with the General Partners) manages $2,417,300,965 in Client regulatory assets on a discretionary basis (including the net asset value of portfolio securities valued as of December 31, 2022 plus uncalled capital commitments as of December 31, 2022) and no Client assets on a non-discretionary basis.